Current and emerging treatments for acute promyelocytic leukemia

References

• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19(4):379–390.
   PubMed Web of Science ®Google Scholar
• de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775–783.
   PubMed Web of Science ®Google Scholar
• Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 1957;159(3):189–194.
   PubMedGoogle Scholar
• Bernard J, Mathe G, Boulay J, et al. Acute promyelocytic leukemia: a study made on 20 cases. Schweiz Med Wochenschr. 1959;89:604–608.
   PubMedGoogle Scholar
• Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489–496.
   PubMed Web of Science ®Google Scholar
• Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature. 1978;274(5671):535–539.
   PubMed Web of Science ®Google Scholar
• Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980;77(5):2936–2940.
   PubMed Web of Science ®Google Scholar
• Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57(6):1000–1004.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515.
   PubMed Web of Science ®Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–3473.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Shi -Z-Z, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328–5335.
   PubMed Web of Science ®Google Scholar
• Wang G, Li W, Cui J, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol. 2004;22(2):63–71.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Lo-Coco F. Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol. 2016;27(8):1474–1481.
   PubMed Web of Science ®Google Scholar
• Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119(1):34–43.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of acute promyelocytic leukemia among hispanics, blacks, asians, and non-hispanic whites in the United States. Eur J Cancer Prev. 2006;15(4):367–370.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer. 2012;118(23):5811–5818.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European leukemianet. Blood. 2009;113(9):1875–1891.
   PubMed Web of Science ®Google Scholar
• Douer D. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):357–367.
   PubMed Web of Science ®Google Scholar
• Mazzarella L, Botteri E, Matthews A, et al. Obesity as a risk factor for acute promyelocytic leukemia. Results from population and case-control studies across western countries and correlation with gene expression in the TCG. Blood. 2016;128:448.
   Web of Science ®Google Scholar
• Tedesco J, Qualtieri J, Head D, et al. High prevalence of obesity in Acute Promyelocytic Leukemia (APL): implications for differentiating agents in APL and metabolic syndrome. Ther Adv Hematol. 2011;2(3):141–145.
   PubMedGoogle Scholar
• Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2012;156(1):24–36.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia. 2011;25(7):1128–1134.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29(5):495–503.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–3179.
   PubMed Web of Science ®Google Scholar
• Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–1283.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–e566.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–510.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Rami AM, Komrokji S, et al. ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk Acute Promyelocytic Leukemia (APL): final results of the SWOG/Alliance/ECOG S0535 trial. Blood. 2016;128:896.
   Web of Science ®Google Scholar
• Ortega JJ, Madero L, Martín G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. J Clin Oncol. 2005;23(30):7632–7640.
   PubMed Web of Science ®Google Scholar
• Testi AM, Biondi A, Coco FL, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447–453.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Lefebvre P, Chomienne C, et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood. 1993;82(12):3560–3563.
   PubMed Web of Science ®Google Scholar
• Muindi JR, Frankel SR, Huselton C, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992;52(8):2138–2142.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American leukemia intergroup study C9710. Blood. 2010;116(19):3751–3757.
   PubMed Web of Science ®Google Scholar
• Osman AEG, Anderson J, Churpek JE, et al. Treatment of acute promyelocytic leukemia in adults. J Oncol Pract. 2018;14(11):649–657.
   PubMed Web of Science ®Google Scholar
• Coutre SE, Othus M, Powell B, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014;165(4):497–503.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–4725.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Diaz-Mediavilla J, Deben G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009;94(9):1242–1249.
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Fong BM, et al. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008;112(9):3587–3590.
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Kwong YL. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk Res. 2008;32(2):357–358.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European leukemianet. Blood. 2019;133(15):1630–1643.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777–2782.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783.
   PubMed Web of Science ®Google Scholar
• Chamoun K, Kantarjian HM, Wang X, et al. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019;125:3219–3224.
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315–3324.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354–3360.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1341–1348.
   PubMed Web of Science ®Google Scholar
• Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000;18(13):2620–2625.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Au WY, Chim CS, et al. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol. 2001;66(4):274–279.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852–3860.
   PubMed Web of Science ®Google Scholar
• Yanada M, Fujisawa S, Sunami K, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013;121(16):3095–3102.
   PubMed Web of Science ®Google Scholar
• Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol. 2003;21(12):2326–2334.
   PubMed Web of Science ®Google Scholar
• Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007;109(7):1355–1359.
   PubMed Web of Science ®Google Scholar
• Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102:407–408.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Koumenis I, Johri A, et al. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2019. doi:10.3324/haematol.2019.229583. [Epub ahead of print]
   Google Scholar
• Gill H, Kumana CR, Yim R, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. Cancer. 2019;125(17):3001–3012.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4221.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med. 2014;371(23):2239–2241.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Liu Y-R, Jia J-S, et al. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987–2989.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu D-P, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879.
   PubMed Web of Science ®Google Scholar
• Yang MH, Wan WQ, Luo JS, et al. Multicenter randomized trial of arsenic trioxide and realgar-indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study. Am J Hematol. 2018;93(12):1467–1473.
   PubMed Web of Science ®Google Scholar
• Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123–2137.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Pagano L, Coco FL, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100(6):1972–1976.
   PubMed Web of Science ®Google Scholar
• Braun T, Cereja S, Chevret S, et al. Evolving characteristics and outcome of secondary Acute Promyelocytic Leukemia (APL): a prospective analysis by the French-Belgian-Swiss APL group. Cancer. 2015;121(14):2393–2399.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Hu J, Lo-Coco F, et al. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597–605.
   PubMed Web of Science ®Google Scholar